Sofosbuvir Patent Expiration
Sofosbuvir is used for treating chronic hepatitis C virus infection as part of combination antiviral therapy. It was first introduced by Gilead Sciences Inc
Sofosbuvir Patents
Given below is the list of patents protecting Sofosbuvir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sovaldi | US7964580 | NA | Mar 26, 2029 | Gilead Sciences Inc |
| Sovaldi |
US7964580 (Pediatric) | NA | Sep 26, 2029 | Gilead Sciences Inc |
| Sovaldi | US8334270 | NA | Mar 21, 2028 | Gilead Sciences Inc |
| Sovaldi |
US8334270 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
| Sovaldi | US8580765 | NA | Mar 21, 2028 | Gilead Sciences Inc |
| Sovaldi |
US8580765 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
| Sovaldi | US8618076 | Nucleoside phosphoramidates | Dec 11, 2030 | Gilead Sciences Inc |
| Sovaldi |
US8618076 (Pediatric) | Nucleoside phosphoramidates | Jun 11, 2031 | Gilead Sciences Inc |
| Sovaldi | US8633309 | Nucleoside phosphoramidates | Mar 26, 2029 | Gilead Sciences Inc |
| Sovaldi |
US8633309 (Pediatric) | Nucleoside phosphoramidates | Sep 26, 2029 | Gilead Sciences Inc |
| Sovaldi | US8889159 | Compositions and methods for treating hepatitis C virus | Mar 26, 2029 | Gilead Sciences Inc |
| Sovaldi |
US8889159 (Pediatric) | Compositions and methods for treating hepatitis C virus | Sep 26, 2029 | Gilead Sciences Inc |
| Sovaldi | US9085573 | NA | Mar 21, 2028 | Gilead Sciences Inc |
| Sovaldi |
US9085573 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
| Sovaldi | US9284342 | Nucleoside phosphoramidates | Sep 13, 2030 | Gilead Sciences Inc |
| Sovaldi |
US9284342 (Pediatric) | Nucleoside phosphoramidates | Mar 13, 2031 | Gilead Sciences Inc |
| Sovaldi | US9549941 | Compositions and methods for treating hepatitis C virus | Mar 26, 2029 | Gilead Sciences Inc |
| Sovaldi |
US9549941 (Pediatric) | Compositions and methods for treating hepatitis C virus | Sep 26, 2029 | Gilead Sciences Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sofosbuvir's patents.
Latest Legal Activities on Sofosbuvir's Patents
Given below is the list recent legal activities going on the following patents of Sofosbuvir.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9549941 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Jul, 2020 | US9549941 |
| Mail Certificate of Correction Memo | 17 Apr, 2018 | US9549941 |
| Certificate of Correction Memo | 11 Apr, 2018 | US9549941 |
| Recordation of Patent Grant Mailed | 24 Jan, 2017 | US9549941 |
| Patent Issue Date Used in PTA Calculation | 24 Jan, 2017 | US9549941 |
| Email Notification | 05 Jan, 2017 | US9549941 |
| Issue Notification Mailed | 04 Jan, 2017 | US9549941 |
| Application Is Considered Ready for Issue | 14 Dec, 2016 | US9549941 |
| Dispatch to FDC | 14 Dec, 2016 | US9549941 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Sofosbuvir Generics
Only one generic application has been filed for Sofosbuvir.
Given below is the list of companies who have filed for Sofosbuvir generic.
1. TEVA PHARMS USA INC
Teva Pharmaceuticals Usa Inc has filed for 1 generic for Sofosbuvir. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 400MG | tablet | Discontinued | ORAL | N/A | Jan 27, 2022 |